Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
TCRX, MIND, ATLO, LLY, PFMT, REAL, ROCC, QMCO, UNH, XFLT
WDFC, IVAN, LLY, MDLA, PEP, SHLS, MTEM, BRDG, DAL, XFLT
NFLX, HOG, JBHT, PPG, JNJ, MTB, MAN
Damien ConoverSector Director